Greater Manchester is officially refusing to adopt Palantir’s Federated Data Platform (FDP) across its National Health Service operations. As the UK government faces a six-month window to evaluate a contract exceeding $400 million, the northern region insists its internally developed system is more effective and trusted by clinicians.
The Anatomy of a High-Stakes Procurement Battle
The UK health landscape sits at a critical architectural crossroads. Back in 2023, the UK tasked American software firm Palantir with creating a national federated data platform designed to consolidate and organize the complex health data generated nationwide. Proponents argue that the system is already reducing wait times, shortening hospital stays, and optimizing operating rooms across participating trusts.
Yet, the rollout has triggered fierce pushback. Protests, petitions, and parliamentary investigations have dogged the partnership due to Palantir’s ongoing work in military conflicts and US government immigration policies. European countries are increasingly reassessing their technical dependencies on American software vendors. Amid this broader geopolitical friction, Greater Manchester has stood as an English region officially rejecting the FDP architecture.
Why Greater Manchester Built Its Own Stack
Instead of plugging into the national repository, NHS Greater Manchester relies on an internally developed platform that has evolved over nearly a decade. Local administrators argue they do not require Palantir’s tools, pointing to public trust and clinical efficiency as core drivers for their defiance.
“Even a technically strong platform will struggle to realize value if clinicians, data controllers, patients or the public do not trust it,” explains Matt Hennessey, chief data and analytics officer at NHS Greater Manchester, in an interview with WIRED. “If we were to fully adopt the FDP… it would be a retrograde step.”
This localized resistance exposes a deep ideological split in healthcare data engineering. National deployment advocates champion the “lift and shift” capability of a centralized platform. Tom Bartlett, an independent IT consultant who previously managed the national FDP rollout as deputy director of data engineering at NHS England, asserts that standardization allows tools built in one trust to be seamlessly implemented elsewhere while providing a unified framework for artificial intelligence to operate across.
Legacy Fragmentation Versus Modern Repositories
To understand why the FDP exists at all, look at the historical infrastructure of the NHS. For years, healthcare personnel have relied on a fragmented mix of digital systems, spreadsheets, paper, and physical whiteboards to track patient flows. When patients transition between care environments, records routinely go missing, occasionally resulting in severe clinical consequences.
Without an integrated data exchange layer, administrators have historically been forced to allocate funding based on incomplete metrics. The FDP attempts to fix this by combining a national repository for identifying care gaps with local databases configured for waitlist management and discharge planning.
However, Greater Manchester’s outright rejection threatens the uniformity of the national strategy. Lawmakers are openly questioning why the rest of the country cannot bypass the American contractor just as the northern health board has done. With the government’s termination window fast approaching ahead of the contract’s potential 2031 expiration, the debate highlights the friction between centralized enterprise software acquisitions and regional sovereignty in public health infrastructure.
The Structural Verdict
- Contract Scale: The national NHS agreement with Palantir exceeds $400 million, with a key government evaluation window arriving ahead of a potential early exit.
- The Dissent: NHS Greater Manchester remains a regional health board refusing the Federated Data Platform.
- The Alternative: The region continues to utilize its own homegrown platform developed over nearly ten years, prioritizing local clinical trust over centralized software standardization.
As the six-month review period ticks down, the clash over Greater Manchester’s refusal forces a reckoning. The central question for British healthcare is no longer just about database performance or API flexibility. It centers on whether proprietary American enterprise software can maintain legitimacy when key regions refuse to run its code.
